PeptiMatrix: Next generation peptide hydrogels for 3D cell culture

PeptiMatrix：用于 3D 细胞培养的下一代肽水凝胶

• 批准号: 10070302
• 金额: $ 34.49万
• 依托单位: PEPTIMATRIX
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10070302
• 关键词: PeptiMatrix; Next; generation; peptide; hydrogels

Current _in vitro_ models of development and disease typically fail to recapitulate the complexities of native tissue microenvironments, leading to a poor extrapolation of _in vitro_ findings to _in vivo_ relevance. This is a major contributing factor to the high attrition rate of new drugs moving from the lab to the clinic, leading to an estimated cost of US$2 billion to bring a new lifesaving therapy to market.Growing recognition of this has led to a recent interest in developing more sophisticated 3D _in vitro_ model platforms which allow for customisation of matrix stiffness and composition. However, despite considerable research effort, no single platform has yet pulled ahead of the competition. With the support of the BBSRC and NC3Rs, we have developed a fully synthetic self-assembling peptide hydrogel (SAPH) platform which aims to address all the current shortcomings of available 3D _in vitro_ model platforms.PeptiMatrix(tm) is chemically well-defined, has limited batch variability, and contains no irrelevant animal-derived material. It can also be customised via a variety of available methods to match the stiffness and composition of any target tissue type. Each formulation of PeptiMatrix(tm) will, therefore, have been specifically tailored to model a specific tissue or tissue type and validated in a relevant cell-based assay.PeptiMatrix(tm) is supplied ready-to-use: simply combine with your cells of interest and plate out. Your cells will then cluster and grow in 3D, in a physiologically relevant and reproducible way. This saves time versus similar products that require complex preparatory steps or require that you customise (and optimise) the hydrogel yourself.

当前的_in Velto_开发和疾病模型通常无法概括天然组织微环境的复杂性，从而导致_in vivo_相关性的_in vinefunce _in _in _in viefunce的推断较差。这是从实验室转移到诊所的新药的高损耗率的主要因素，导致估计成本为20亿美元，以将新的救生疗法带到市场上。对此，人们对此产生了浓厚的兴趣，这引起了人们对更复杂的3D _INTELRO_模型的产生兴趣，从而允许Matrix刚性僵硬和构图定制。但是，尽管进行了大量的研究工作，但在竞争中尚未提前升空。在BBSRC和NC3RS的支持下，我们开发了一个完全合成的自组装肽水凝胶（SAPH）平台，旨在解决所有当前可用的3D _in intervro_模型平台的缺点。peptimatrix（tm）是化学上良好的批次变化，限制了批处理可变性，并且没有无线电材料。它也可以通过多种可用方法来定制，以匹配任何目标组织类型的刚度和组成。因此，每种肽（TM）的配方将专门定制用于建模特定的组织或组织类型，并在相关的基于细胞的测定中进行验证。肽映射（TM）可用来使用：只需与您的感兴趣和板块结合使用。然后，您的细胞将以生理相关和可再现的方式聚集并在3D中生长。这节省了时间与需要复杂的预备步骤或需要自定义（并优化）水凝胶的类似产品。